Clinical Trials

FaR-RMS

Frontline and Relapse Study in RhabdomyoSarcoma Study

Soft Tissue Sarcomas

Status: Open | New Zealand , NSW , VIC , WA

Patients diagnosed with rhabdomyosarcoma are treated with chemotherapy, radiotherapy and surgery, but many do not survive. Our United Kingdom and European colleagues have developed a new overarching trial, FaR-RMS study, which includes optimising radiotherapy, testing the latest promising agents, new combinations and analysing the length of therapy. Several research questions are addressed within FaR-RMS and new drugs can be rapidly added. Opening FaR-RMS in Australia gives new hope to all patients battling rhabdomyosarcoma.

Disease Stage: Newly diagnosed, relapsed and progressive

Patient Age Range: All ages

Trial Sponsors:

  • International: University of Birmingham
  • National: ANZCHOG

ANZCHOG acknowledges the valuable support of FaR-RMS by the Australian Government through the Medical Research Future Fund.

logo-australian-gov.png

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.